Clinical trial NCT03847090 - References

Enteric Hyperoxaluria — Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

Citation(s)

•   Langman CB, Grujic D, Pease RM, Easter L, Nezzer J, Margolin A, Brettman L
  A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme. Am J Nephrol. 2016;44(2):150-8. doi: 10.1159/000448766. Epub 2016 Aug 17.
•   Lingeman JE, Pareek G, Easter L, Pease R, Grujic D, Brettman L, Langman CB
  ALLN-177, oral enzyme therapy for hyperoxaluria. Int Urol Nephrol. 2019 Apr;51(4):601-608. doi: 10.1007/s11255-019-02098-1. Epub 2019 Feb 19.

Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)

Details for clinical trial NCT03847090